Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GLMN | Q92990 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28146962 | 1.00 | DPP4 (0.50) | DPP4DPP8DPP9FAPALDH1A1 | |
| SCHEMBL17048409 | 0.83 | DPP4 (0.53) | DPP4DPP8DPP9FAPALDH1A1 | |
| SCHEMBL15114218 | 0.80 | GRIN2D (0.47) | DPP4DPP8DPP9FAPALDH1A1 | |
| SCHEMBL7415894 | 0.79 | GRIN2D (0.46) | DPP4EPHX2 | |
| SCHEMBL12735378 | 0.78 | DPP4 (0.56) | DPP4DPP8DPP9FAPALDH1A1 | |
| SCHEMBL160300 | 0.77 | DPP4 (0.58) | DPP4DPP8DPP9FAPALDH1A1 | |
| SCHEMBL19160132 | 0.77 | DPP4 (0.45) | DPP4DPP8DPP9FAPALDH1A1 | |
| SCHEMBL27631871 | 0.76 | DPP4 (0.47) | DPP4DPP8DPP9FAPALDH1A1 | |
| SCHEMBL12354573 | 0.76 | DPP4 (0.53) | DPP4DPP8DPP9FAPALDH1A1 | |
| SCHEMBL13444794 | 0.74 | GRIN2D (0.56) | DPP4DPP8DPP9FAPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110092738-A | The preparation method of vildagliptin | 深圳市第二人民医院 | 2019-08-06 | — | — | CN | disclosed |
| CN-105287604-B | Pharmaceutical composition containing ibat inhibitor and bile acid binding agent | 阿尔比里奥公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-109111386-A | The synthetic method of L- prolineamide | 南京红杉生物科技有限公司 | 2019-01-01 | — | — | CN | disclosed |
| CN-108452311-A | Composition for enhancing energetic supersession and method | 纽斯尔特科学公司 | 2018-08-28 | — | — | CN | disclosed |
| CN-108295058-A | Composition for enhancing energetic supersession and method | 纽斯尔特科学公司 | 2018-07-20 | — | — | CN | disclosed |
| CN-104918610-B | compositions and methods for enhancing energy metabolism | 纽斯尔特科学公司 | 2018-04-10 | — | — | CN | disclosed |
| CN-104672243-B | The preparation method of vildagliptin degradation impurity | 华润赛科药业有限责任公司 | 2017-09-22 | — | — | CN | disclosed |
| CN-104557943-B | Preparation method of vildagliptin impurities | 扬子江药业集团四川海蓉药业有限公司 | 2017-05-03 | — | — | CN | disclosed |
| CN-105853387-A | Stable vildagliptin capsule drug composition | 天津汉瑞药业有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-105777602-A | Stable vildagliptin compound | 天津汉瑞药业有限公司 | 2016-07-20 | — | — | CN | disclosed |
| WO-2013020108-A2 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PANCREATITIS | Lumena Pharmaceuticals, Inc. (US) | 2013-02-07 | — | — | WO | disclosed |
| CN-102316872-A | Bile acid recycling inhibitor for treating obesity and diabetes | SATIOGEN PHARMACEUTICALS INC | 2012-01-11 | — | — | CN | disclosed |
| WO-2011150286-A2 | BILE ACID RECYCLING INHIBITORS AND SATIOGENS FOR TREATMENT OF DIABETES, OBESITY, AND INFLAMMATORY GASTROINTESTINAL CONDITIONS | SATIOGEN PHARMACEUTICALS,INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| CN-101208085-B | Modified release formulations of 1- [ (3-hydroxy-adamantyl-1-ylamino) -acetyl ] -pyrrolidinyl-2(s) -carbonitrile | NOVARTIS AG | 2011-01-05 | — | — | CN | disclosed |
| CN-101932321-A | Combination therapy comprising an SGLT inhibitor and a DPP4 inhibitor | MITSUBISHI TANABE PHARMA CORP | 2010-12-29 | — | — | CN | disclosed |
| WO-2010062863-A2 | COMPOSITIONS CONTAINING SATIOGENS AND METHODS OF USE | SATIOGEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| CN-101277719-A | Medical agent containing insulin resistance improving agent | DAIICHI SANKYO CO LTD (JP) | 2008-10-01 | — | — | CN | disclosed |
| CN-101208085-A | Modified release formulations of 1- [ (3-hydroxy-adamantyl-1-ylamino) -acetyl ] -pyrrolidinyl-2(s) -carbonitrile | NOVARTIS AG (CH) | 2008-06-25 | — | — | CN | disclosed |
| CN-1901881-A | Compositions and dosage forms for enhanced absorption | ALZA CORP (US) | 2007-01-24 | — | — | CN | disclosed |
| CN-1700911-A | Combination drug | EISAI CO LTD (JP) | 2005-11-23 | — | — | CN | disclosed |